| Year |
Citation |
Score |
| 2023 |
Hillman SL, Jatoi A, Strand CA, Perlmutter J, George S, Mandrekar SJ. Rates of and Factors Associated With Patient Withdrawal of Consent in Cancer Clinical Trials. Jama Oncology. PMID 37347469 DOI: 10.1001/jamaoncol.2023.1648 |
0.327 |
|
| 2022 |
Kehl KL, Zahrieh D, Yang P, Hillman SL, Tan AD, Sands JM, Oxnard GR, Gillaspie EA, Wigle D, Malik S, Stinchcombe TE, Ramalingam SS, Kelly K, Govindan R, Mandrekar SJ, et al. Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). Jama Oncology. PMID 35297944 DOI: 10.1001/jamaoncol.2022.0039 |
0.316 |
|
| 2022 |
Remon J, Lacas B, Herbst R, Reck M, Garon EB, Scagliotti GV, Ramlau R, Hanna N, Vansteenkiste J, Yoh K, Groen HJM, Heymach JV, Mandrekar SJ, Okamoto I, Neal JW, et al. ANtiangiogenic Second-line Lung cancer Meta-Analysis on individual patient data in non-small cell lung cancer: ANSELMA. European Journal of Cancer (Oxford, England : 1990). 166: 112-125. PMID 35286903 DOI: 10.1016/j.ejca.2022.02.002 |
0.301 |
|
| 2021 |
Boughey JC, Snyder RA, Kantor O, Zheng L, Chawla A, Nguyen TT, Hillman SL, Hahn OM, Mandrekar SJ, Roland CL. Impact of the COVID-19 Pandemic on Cancer Clinical Trials. Annals of Surgical Oncology. PMID 34236550 DOI: 10.1245/s10434-021-10406-2 |
0.32 |
|
| 2021 |
Almodallal Y, Duong Q, Satele D, Novotny P, Cook KD, Chauhan C, Daiss MK, Le-Rademacher J, Looker S, Martin N, Smestad MF, Winham SJ, Mandrekar SJ, Jatoi A. Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent Forms. Jco Oncology Practice. OP2100071. PMID 34125586 DOI: 10.1200/OP.21.00071 |
0.315 |
|
| 2021 |
Sands JM, Mandrekar SJ, Kozono D, Oxnard GR, Hillman SL, Wigle DA, Govindan R, Carlisle J, Gray J, Salama JK, Raez L, Ganti A, Foster N, Malik S, Bradley J, et al. Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy. PMID 33878954 DOI: 10.2217/imt-2021-0019 |
0.364 |
|
| 2020 |
Le-Rademacher JG, Hillman S, Storrick E, Mahoney MR, Thall PF, Jatoi A, Mandrekar SJ. Adverse Event Burden Score-A Versatile Summary Measure for Cancer Clinical Trials. Cancers. 12. PMID 33158080 DOI: 10.3390/cancers12113251 |
0.306 |
|
| 2020 |
Le-Rademacher J, Lopez C, Wolfe E, Foster NR, Mandrekar SJ, Wang X, Kumar R, Adjei A, Jatoi A. Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients. Journal of Cachexia, Sarcopenia and Muscle. PMID 32940014 DOI: 10.1002/Jcsm.12625 |
0.398 |
|
| 2020 |
Dahlberg SE, Korn EL, Le-Rademacher J, Mandrekar SJ. Clinical versus Statistical Significance in Studies of Thoracic Malignancies. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32580055 DOI: 10.1016/J.Jtho.2020.06.007 |
0.325 |
|
| 2020 |
Uprety D, Mandrekar SJ, Wigle D, Roden AC, Adjei AA. Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer - Current Concepts and Future Approaches. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32522713 DOI: 10.1016/J.Jtho.2020.05.020 |
0.466 |
|
| 2020 |
Llovet JM, Villanueva A, Marrero JA, Schwartz M, Meyer T, Galle PR, Lencioni R, Greten TF, Kudo M, Mandrekar SJ, Zhu AX, Finn RS, Roberts LR. Trial Design and Endpoints in hepatocellular carcinoma: AASLD Consensus Conference. Hepatology (Baltimore, Md.). PMID 32430997 DOI: 10.1002/Hep.31327 |
0.397 |
|
| 2020 |
An MW, Duong Q, Le-Rademacher J, Mandrekar SJ. Principles of Good Clinical Trial Design. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 32417343 DOI: 10.1016/J.Jtho.2020.05.005 |
0.397 |
|
| 2020 |
Duong Q, Mandrekar SJ, Winham SJ, Cook K, Jatoi A, Le-Rademacher JG. Understanding Verbosity: Funding Source and the Length of Consent Forms for Cancer Clinical Trials. Journal of Cancer Education : the Official Journal of the American Association For Cancer Education. PMID 32385740 DOI: 10.1007/S13187-020-01757-7 |
0.409 |
|
| 2020 |
An MW, Tang J, Grothey A, Sargent DJ, Ou FS, Mandrekar SJ. Missing tumor measurement (TM) data in the search for alternative TM-based endpoints in cancer clinical trials. Contemporary Clinical Trials Communications. 17: 100492. PMID 31872158 DOI: 10.1016/J.Conctc.2019.100492 |
0.394 |
|
| 2020 |
Sands J, Mandrekar SJ, Oxnard GR, Kozono DE, Hillman SL, Dahlberg SE, Sun Z, Chaft JE, Govindan R, Gerber DE, Gray JE, Malik SM, Mooney MM, Janne PA, Vokes EE, et al. ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC. Journal of Clinical Oncology. 38: TPS9077-TPS9077. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps9077 |
0.444 |
|
| 2019 |
Parikh K, Mandrekar SJ, Allen-Ziegler K, Esplin B, Tan AD, Marchello B, Adjei AA, Molina JR. A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance). The Oncologist. PMID 31872928 DOI: 10.1634/Theoncologist.2019-0574 |
0.386 |
|
| 2019 |
Döhner K, Thiede C, Jahn N, Panina E, Gambietz A, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Voso MT, Ottone T, Nomdedeu JF, Mandrekar SJ, et al. Impact of NPM1/FLT3-ITD genotypes defined by the2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood. PMID 31826241 DOI: 10.1182/Blood.2019002697 |
0.357 |
|
| 2019 |
Schenk EL, Mandrekar SJ, Dy GK, Aubry MC, Tan AD, Dakhil SR, Sachs BA, Nieva JJ, Bertino E, Lee Hann C, Schild SE, Wadsworth TW, Adjei AA, Molina JR. A randomized double-blind phase II study of the Seneca Valley Virus (NTX-010) vs placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least 4 cycles of platinum-based chemotherapy: NCCTG (Alliance) N0923 Study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31605793 DOI: 10.1016/J.Jtho.2019.09.083 |
0.452 |
|
| 2019 |
Le-Rademacher JG, Storrick EM, Jatoi A, Mandrekar SJ. Physician-Reported Experience and Understanding of Adverse Event Attribution in Cancer Clinical Trials. Mayo Clinic Proceedings. Innovations, Quality & Outcomes. 3: 176-182. PMID 31193907 DOI: 10.1016/J.Mayocpiqo.2019.01.002 |
0.389 |
|
| 2019 |
Yin J, LaPlant B, Uy GL, Marcucci G, Blum W, Larson RA, Stone RM, Mandrekar SJ. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614). Blood Advances. 3: 1714-1721. PMID 31171508 DOI: 10.1182/Bloodadvances.2018026112 |
0.381 |
|
| 2019 |
George GC, Barata PC, Campbell A, Chen A, Cortes JE, Hyman DM, Jones L, Karagiannis T, Klaar S, Le-Rademacher JG, LoRusso P, Mandrekar SJ, Merino DM, Minasian LM, Mitchell SA, et al. Improving attribution of adverse events in oncology clinical trials. Cancer Treatment Reviews. 76: 33-40. PMID 31108240 DOI: 10.1016/J.Ctrv.2019.04.004 |
0.406 |
|
| 2019 |
Litière S, Isaac G, De Vries EGE, Bogaerts J, Chen A, Dancey J, Ford R, Gwyther S, Hoekstra O, Huang E, Lin N, Liu Y, Mandrekar S, Schwartz LH, Shankar L, et al. RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1801100. PMID 30860949 DOI: 10.1200/Jco.18.01100 |
0.437 |
|
| 2019 |
Ruppert AS, Yin J, Davidian M, Tsiatis AA, Byrd JC, Woyach JA, Mandrekar SJ. Application of a Sequential Multiple Assignment Randomized Trial (SMART) Design in Older Patients with Chronic Lymphocytic Leukemia. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 30799502 DOI: 10.1093/Annonc/Mdz053 |
0.404 |
|
| 2019 |
Woyach J, Ruppert AS, Perez G, Booth AM, Feldman D, Dib EG, Jatoi A, Le-Rademacher J, Heerema NA, Lozanski G, Little R, Ding W, Hill BT, Stone RM, Mandrekar SJ, et al. Alliance A041702: A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL) Blood. 134: 1751-1751. DOI: 10.1182/Blood-2019-127102 |
0.325 |
|
| 2019 |
Zahrieh D, McMurray RP, Foster NR, Limburg PJ, Mandrekar SJ. Abstract 5092: Participant satisfaction with cancer chemoprevention clinical trials: The Mayo Clinic Cancer Prevention Network (CPN) experience Cancer Research. 79: 5092-5092. DOI: 10.1158/1538-7445.Sabcs18-5092 |
0.393 |
|
| 2018 |
Loibl S, Metzger O, Mandrekar SJ, Mundhenke C, Seiler S, Valagussa P, DeMichele A, Lim E, Tripathy D, Winer EP, Huang C, Carey L, Francis P, Miller KD, Goetz MP, et al. PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). Annals of Oncology : Official Journal of the European Society For Medical Oncology. 29: viii121. PMID 32136159 DOI: 10.1093/Annonc/Mdy272.357 |
0.344 |
|
| 2018 |
Roboz GJ, Mandrekar SJ, Desai P, Laumann K, Walker AR, Wang ES, Kolitz JE, Powell BL, Attar EC, Stock W, Bloomfield CD, Kohlschmidt J, Mrózek K, Hassane DC, Garraway L, et al. Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance). Blood Advances. 2: 3608-3617. PMID 30567725 DOI: 10.1182/Bloodadvances.2018023689 |
0.407 |
|
| 2018 |
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, Bartlett NL, Brander DM, Barr PM, Rogers KA, Parikh SA, Coutre S, Hurria A, Brown JR, Lozanski G, ... ... Mandrekar SJ, et al. Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL. The New England Journal of Medicine. PMID 30501481 DOI: 10.1056/Nejmoa1812836 |
0.386 |
|
| 2018 |
Du Y, Yin J, Sargent DJ, Mandrekar SJ. An adaptive multi-stage phase I dose-finding design incorporating continuous efficacy and toxicity data from multiple treatment cycles. Journal of Biopharmaceutical Statistics. 1-16. PMID 30403559 DOI: 10.1080/10543406.2018.1535497 |
0.361 |
|
| 2018 |
Le-Rademacher J, Dahlberg S, Lee JJ, Adjei AA, Mandrekar SJ. Biomarker Clinical Trials in Lung Cancer: Design, Logistics, Challenges, and Practical Considerations. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 30194034 DOI: 10.1016/J.Jtho.2018.08.2019 |
0.483 |
|
| 2018 |
Le-Rademacher JG, Peterson RA, Therneau TM, Sanford BL, Stone RM, Mandrekar SJ. Application of multi-state models in cancer clinical trials. Clinical Trials (London, England). 1740774518789098. PMID 30035644 DOI: 10.1177/1740774518789098 |
0.384 |
|
| 2018 |
Byrd JC, Ruppert AS, Heerema NA, Halvorson AE, Hoke E, Smith MR, Godwin JE, Couban S, Fehniger TA, Thirman MJ, Tallman MS, Appelbaum FR, Stone RM, Robinson S, Chang JE, ... Mandrekar SJ, et al. Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Advances. 2: 1705-1718. PMID 30030269 DOI: 10.1182/Bloodadvances.2017015396 |
0.33 |
|
| 2018 |
Yin J, Dahlberg SE, Mandrekar SJ. Evaluation of End Points in Cancer Clinical Trials. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29706308 DOI: 10.1016/J.Jtho.2018.04.004 |
0.408 |
|
| 2018 |
Le-Rademacher J, Hillman SL, Meyers J, Loprinzi CL, Limburg PJ, Mandrekar SJ. Statistical controversies in clinical research: Value of adverse events relatedness to study treatment: analyses of data from randomized double-blind placebo-controlled clinical trials. Annals of Oncology : Official Journal of the European Society For Medical Oncology. 28: 1183-1190. PMID 28184420 DOI: 10.1093/Annonc/Mdx043 |
0.433 |
|
| 2018 |
Le-Rademacher J, Storrrick EM, Jatoi A, Mandrekar SJ. Physician experience and understanding of clinical trial adverse event attribution. Journal of Clinical Oncology. 36: e14524-e14524. DOI: 10.1200/Jco.2018.36.15_Suppl.E14524 |
0.404 |
|
| 2018 |
Yin J, Uy GL, Laplant B, Storrick E, Marcucci G, Fernandez HF, Sun Z, Litzow MR, Othus M, Appelbaum FR, Larson RA, Stone RM, Mandrekar SJ. Event-Free Survival As a Surrogate Endpoint for Overall Survival in Previously Untreated Acute Myeloid Leukemia: An Individual Patient-Level Analysis of Multiple Randomized Trials (Alliance A151614) Blood. 132: 1386-1386. DOI: 10.1182/Blood-2018-99-113902 |
0.464 |
|
| 2018 |
Metzger O, Mandrekar S, Loibl S, Mundhenke C, Seiler S, Valagussa P, Lim E, Tripathy D, Winer E, Huang C, Carey L, Francis P, Miller K, Goetz M, Prat A, et al. Abstract OT3-05-07: PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot3-05-07 |
0.435 |
|
| 2018 |
Mu R, Yuan Y, Xu J, Mandrekar SJ, Yin J. gBOIN: a unified model‐assisted phase I trial design accounting for toxicity grades, and binary or continuous end points Journal of the Royal Statistical Society: Series C (Applied Statistics). 68: 289-308. DOI: 10.1111/Rssc.12263 |
0.329 |
|
| 2017 |
Uy GL, Mandrekar SJ, Laumann K, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Sanford B, Blum WG, Bloomfield CD, et al. A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001. Blood Advances. 1: 331-340. PMID 29034366 DOI: 10.1182/Bloodadvances.2016003053 |
0.402 |
|
| 2017 |
Renfro LA, Mandrekar SJ. Definitions and Statistical Properties of Master Protocols for Personalized Medicine in Oncology. Journal of Biopharmaceutical Statistics. PMID 28877008 DOI: 10.1080/10543406.2017.1372778 |
0.425 |
|
| 2017 |
Yin J, Paoletti X, Sargent DJ, Mandrekar SJ. Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data. Clinical Trials (London, England). 1740774517723829. PMID 28764555 DOI: 10.1177/1740774517723829 |
0.359 |
|
| 2017 |
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer S, Bloomfield CD, Thiede C, Prior TW, Döhner K, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. The New England Journal of Medicine. PMID 28644114 DOI: 10.1056/Nejmoa1614359 |
0.395 |
|
| 2017 |
Yan F, Mandrekar SJ, Yuan Y. Keyboard: A Novel Bayesian Toxicity Probability Interval Design for Phase I Clinical Trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28546227 DOI: 10.1158/1078-0432.Ccr-17-0220 |
0.343 |
|
| 2017 |
Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. The Lancet. Oncology. 18: e143-e152. PMID 28271869 DOI: 10.1016/S1470-2045(17)30074-8 |
0.427 |
|
| 2017 |
Ruppert AS, Byrd JC, Heerema NA, Smith MR, Godwin JE, Couban S, Fehniger TA, Thirman M, Halvorson AE, Tallman MS, Appelbaum FR, Stone RM, Robinson S, Chang JE, Mandrekar SJ, et al. A genetic risk-stratified, randomized phase 2 intergroup study of fludarabine/antibody combinations in symptomatic, untreated chronic lymphocytic leukemia (CLL): Results from Cancer and Leukemia Group B (CALGB) 10404 (Alliance). Journal of Clinical Oncology. 35: 7503-7503. DOI: 10.1200/Jco.2017.35.15_Suppl.7503 |
0.359 |
|
| 2017 |
Litière S, Isaac G, Vries ED, Bogaerts J, Chen AP, Dancey J, Ford R, Gwyther SJ, Hoekstra OS, Huang E, Lin NU, Liu Y, Mandrekar SJ, Schwartz LH, Shankar L, et al. Validation of RECIST 1.1 for use with cytotoxic agents and targeted cancer agents (TCA): Results of a RECIST Working Group analysis of a 50 clinical trials pooled individual patient database. Journal of Clinical Oncology. 35: 2534-2534. DOI: 10.1200/Jco.2017.35.15_Suppl.2534 |
0.479 |
|
| 2017 |
Döhner K, Thiede C, Larson RA, Prior TW, Marcucci G, Jones D, Krauter J, Heuser M, Coco FL, Ottone T, Nomdedeu J, Mandrekar SJ, Sanford BL, Laumann K, Geyer SM, et al. Prognostic Impact of NPM1/FLT3-ITD genotypes from Randomized Patients with Acute Myeloid Leukemia (AML) Treated within the International Ratify Study Blood. 130: 467-467. DOI: 10.1182/Blood.V130.Suppl_1.467.467 |
0.353 |
|
| 2017 |
Stone RM, Mandrekar SJ, Sanford BL, Laumann K, Geyer SM, Bloomfield CD, Dohner K, Thiede C, Marcucci G, Coco FL, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, et al. The Addition of Midostaurin to Standard Chemotherapy Decreases Cumulative Incidence of Relapse (CIR) in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603 / RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations Blood. 130: 2580-2580. DOI: 10.1182/Blood.V130.Suppl_1.2580.2580 |
0.341 |
|
| 2017 |
Larson RA, Mandrekar SJ, Sanford BL, Laumann K, Geyer SM, Bloomfield CD, Thiede C, Prior TW, Dohner K, Marcucci G, Coco FL, Klisovic RB, Wei A, Sierra J, Sanz MA, et al. An Analysis of Maintenance Therapy and Post-Midostaurin Outcomes in the International Prospective Randomized, Placebo-Controlled, Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) for Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with FLT3 Mutations Blood. 130: 145-145. DOI: 10.1182/Blood.V130.Suppl_1.145.145 |
0.364 |
|
| 2016 |
Lam S, Mandrekar SJ, Gesthalter Y, Allen Ziegler KL, Seisler DK, Midthun DE, Mao JT, Aubry MC, McWilliams A, Sin DD, Shaipanich T, Liu G, Johnson E, Bild AH, Lenburg ME, et al. A Randomized Phase IIb Trial of myo-Inositol in Smokers with Bronchial Dysplasia. Cancer Prevention Research (Philadelphia, Pa.). PMID 27658890 DOI: 10.1158/1940-6207.Capr-15-0254 |
0.424 |
|
| 2016 |
Pang HH, Wang X, Stinchcombe TE, Wong ML, Cheng P, Ganti AK, Sargent DJ, Zhang Y, Hu C, Mandrekar SJ, Redman MW, Manola JB, Schilsky RL, Cohen HJ, Bradley JD, et al. Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 27646951 DOI: 10.1200/Jco.2016.67.7088 |
0.434 |
|
| 2016 |
Yin J, Qin R, Ezzalfani M, Sargent DJ, Mandrekar SJ. A Bayesian dose-finding design incorporating toxicity data from multiple treatment cycles. Statistics in Medicine. PMID 27633877 DOI: 10.1002/Sim.7134 |
0.357 |
|
| 2016 |
Zhang Q, Freidlin B, Korn EL, Halabi S, Mandrekar S, Dignam JJ. Comparison of futility monitoring guidelines using completed phase III oncology trials. Clinical Trials (London, England). PMID 27590208 DOI: 10.1177/1740774516666502 |
0.4 |
|
| 2016 |
Schwartz LH, Seymour L, Litière S, Ford R, Gwyther S, Mandrekar S, Shankar L, Bogaerts J, Chen A, Dancey J, Hayes W, Hodi FS, Hoekstra OS, Huang EP, Lin N, et al. RECIST 1.1 - Standardisation and disease-specific adaptations: Perspectives from the RECIST Working Group. European Journal of Cancer (Oxford, England : 1990). PMID 27237360 DOI: 10.1016/J.Ejca.2016.03.082 |
0.401 |
|
| 2016 |
Kent MS, Mandrekar SJ, Landreneau R, Nichols F, Foster NR, DiPetrillo TA, Meyers B, Heron DE, Jones DR, Tan AD, Starnes S, Putnam JB, Fernando HC. A Nomogram to Predict Recurrence and Survival of High-Risk Patients Undergoing Sublobar Resection for Lung Cancer: An Analysis of a Multicenter Prospective Study (ACOSOG Z4032). The Annals of Thoracic Surgery. PMID 27101729 DOI: 10.1016/J.Athoracsur.2016.01.063 |
0.418 |
|
| 2016 |
Kent MS, Mandrekar SJ, Landreneau R, Nichols F, DiPetrillo TA, Meyers B, Heron DE, Jones DR, Tan AD, Starnes S, Putnam JB, Fernando HC. Impact of Sublobar Resection on Pulmonary Function: Long-Term Results from American College of Surgeons Oncology Group Z4032 (Alliance). The Annals of Thoracic Surgery. PMID 27101728 DOI: 10.1016/J.Athoracsur.2016.01.069 |
0.312 |
|
| 2016 |
Renfro LA, An MW, Mandrekar SJ. Precision oncology: A new era of cancer clinical trials. Cancer Letters. PMID 26987624 DOI: 10.1016/J.Canlet.2016.03.015 |
0.446 |
|
| 2016 |
Renfro LA, Mallick H, An MW, Sargent DJ, Mandrekar SJ. Clinical trial designs incorporating predictive biomarkers. Cancer Treatment Reviews. 43: 74-82. PMID 26827695 DOI: 10.1016/J.Ctrv.2015.12.008 |
0.486 |
|
| 2016 |
Le-Rademacher J, Hillman S, Meyers JP, Loprinzi CL, Limburg PJ, Mandrekar SJ. Adverse event (AE) attribution in symptom intervention and cancer prevention trials. Journal of Clinical Oncology. 34: e18111-e18111. DOI: 10.1200/Jco.2016.34.15_Suppl.E18111 |
0.352 |
|
| 2016 |
Yin J, Laplant BR, Uy GL, Marcucci G, Blum W, Larson RA, Stone RM, Mandrekar S. Impact of the Timing of Complete Remission and Transplantation on Estimates of Event-Free Survival in Acute Myeloid Leukemia Blood. 128: 214-214. DOI: 10.1182/Blood.V128.22.214.214 |
0.428 |
|
| 2015 |
Govindan R, Mandrekar SJ, Gerber DE, Oxnard GR, Dahlberg SE, Chaft J, Malik S, Mooney M, Abrams JS, Jänne PA, Gandara DR, Ramalingam SS, Vokes EE. ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 5439-44. PMID 26672084 DOI: 10.1158/1078-0432.Ccr-15-0354 |
0.442 |
|
| 2015 |
An MW, Han Y, Meyers JP, Bogaerts J, Sargent DJ, Mandrekar SJ. Clinical Utility of Metrics Based on Tumor Measurements in Phase II Trials to Predict Overall Survival Outcomes in Phase III Trials by Using Resampling Methods. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 26503199 DOI: 10.1200/Jco.2015.60.8778 |
0.413 |
|
| 2015 |
Alden RS, Mandrekar SJ, Oxnard GR. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials. Chinese Clinical Oncology. 4: 37. PMID 26408304 DOI: 10.3978/J.Issn.2304-3865.2015.09.03 |
0.48 |
|
| 2015 |
Zayed AA, Mandrekar SJ, Haluska P. Molecular and clinical implementations of ovarian cancer mouse avatar models. Chinese Clinical Oncology. 4: 30. PMID 26408297 DOI: 10.3978/J.Issn.2304-3865.2015.04.01 |
0.402 |
|
| 2015 |
Sargent DJ, Mandrekar S, Grothey A. Introduction to special issue on biomarker-based clinical trial designs in oncology. Chinese Clinical Oncology. 4: 28. PMID 26408295 DOI: 10.3978/J.Issn.2304-3865.2015.09.05 |
0.401 |
|
| 2015 |
An MW, Dong X, Meyers J, Han Y, Grothey A, Bogaerts J, Sargent DJ, Mandrekar SJ. Evaluating Continuous Tumor Measurement-Based Metrics as Phase II Endpoints for Predicting Overall Survival. Journal of the National Cancer Institute. 107. PMID 26296640 DOI: 10.1093/Jnci/Djv239 |
0.343 |
|
| 2015 |
Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Shibata T, Saijo N, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 1099-106. PMID 26134227 DOI: 10.1097/Jto.0000000000000548 |
0.476 |
|
| 2015 |
Mansfield A, Mandrekar S. Radiotherapy for extensive stage small-cell lung cancer. Lancet (London, England). 385: 1291. PMID 25890909 DOI: 10.1016/S0140-6736(15)60676-6 |
0.359 |
|
| 2015 |
An MW, Lu X, Sargent DJ, Mandrekar SJ. The direct assignment option as a modular design component: an example for the setting of two predefined subgroups. Computational and Mathematical Methods in Medicine. 2015: 210817. PMID 25649690 DOI: 10.1155/2015/210817 |
0.346 |
|
| 2015 |
Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, DiPetrillo TA, Meyers BF, Heron DE, Hillman SL, Jones DR, Starnes SL, Tan AD, Daly BD, Putnam JB. Analysis of longitudinal quality-of-life data in high-risk operable patients with lung cancer: results from the ACOSOG Z4032 (Alliance) multicenter randomized trial. The Journal of Thoracic and Cardiovascular Surgery. 149: 718-25; discussion 7. PMID 25500100 DOI: 10.1016/J.Jtcvs.2014.11.003 |
0.401 |
|
| 2015 |
Zhao Y, Foster NR, Meyers JP, Thomas SP, Northfelt DW, Rowland KM, Mattar BI, Johnson DB, Molina JR, Mandrekar SJ, Schild SE, Bearden JD, Aubry MC, Adjei AA. A phase I/II study of bortezomib in combination with paclitaxel, carboplatin, and concurrent thoracic radiation therapy for non-small-cell lung cancer: North Central Cancer Treatment Group (NCCTG)-N0321. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 10: 172-80. PMID 25247339 DOI: 10.1097/Jto.0000000000000383 |
0.398 |
|
| 2015 |
Renfro LA, Mandrekar SJ. Targeted therapies in oncology: perspectives on trial designs and practical considerations Clinical Investigation. 5: 117-119. DOI: 10.4155/Cli.14.124 |
0.358 |
|
| 2015 |
Gerber DE, Oxnard GR, Mandrekar SJ, Dahlberg SE, Malik SM, Mooney MM, Abrams JS, Janne PA, Li T, Ramalingam SS, Vokes EE, Govindan R. ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer. Journal of Clinical Oncology. 33: TPS7583-TPS7583. DOI: 10.1200/Jco.2015.33.15_Suppl.Tps7583 |
0.449 |
|
| 2015 |
Stone RM, Mandrekar S, Sanford BL, Geyer S, Bloomfield CD, Dohner K, Thiede C, Marcucci G, Lo-Coco F, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, Witte Td, et al. The Multi-Kinase Inhibitor Midostaurin (M) Prolongs Survival Compared with Placebo (P) in Combination with Daunorubicin (D)/Cytarabine (C) Induction (ind), High-Dose C Consolidation (consol), and As Maintenance (maint) Therapy in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients (pts) Age 18-60 with FLT3 Mutations (muts): An International Prospective Randomized (rand) P-Controlled Double-Blind Trial (CALGB 10603/RATIFY [Alliance]) Blood. 126: 6-6. DOI: 10.1182/Blood.V126.23.6.6 |
0.349 |
|
| 2015 |
Uy GL, Mandrekar S, Laumann K, Sanford B, Marcucci G, Zhao W, Levis MJ, Klepin HD, Baer MR, Powell BL, Westervelt P, DeAngelo DJ, Stock W, Bloomfield CD, Byrd JC, et al. Addition of Sorafenib to Chemotherapy Improves the Overall Survival of Older Adults with FLT3-ITD Mutated Acute Myeloid Leukemia (AML) (Alliance C11001) Blood. 126: 319-319. DOI: 10.1182/Blood.V126.23.319.319 |
0.379 |
|
| 2014 |
Millen BA, Dmitrienko A, Mandrekar SJ, Zhang Z, Williams D. Multipopulation Tailoring Clinical Trials: Design, Analysis, and Inference Considerations. Therapeutic Innovation & Regulatory Science. 48: 453-462. PMID 30235572 DOI: 10.1177/2168479013519630 |
0.354 |
|
| 2014 |
Mandrekar SJ, Sargent DJ. Drug designs fulfilling the requirements of clinical trials aiming at personalizing medicine. Chinese Clinical Oncology. 3: 14. PMID 25414851 DOI: 10.3978/J.Issn.2304-3865.2014.05.03 |
0.431 |
|
| 2014 |
Dy GK, Molina JR, Qi Y, Ansari R, Thomas S, Ross HJ, Soori G, Anderson D, Aubry MC, Meyers J, Adjei AA, Mandrekar S, Adjei AA. NCCTG N0821 (Alliance): a phase II first-line study of pemetrexed, carboplatin, and bevacizumab in elderly patients with advanced nonsquamous non-small-cell lung cancer with good performance status. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 9: 1146-53. PMID 25157767 DOI: 10.1097/Jto.0000000000000217 |
0.415 |
|
| 2014 |
Fernando HC, Landreneau RJ, Mandrekar SJ, Nichols FC, Hillman SL, Heron DE, Meyers BF, DiPetrillo TA, Jones DR, Starnes SL, Tan AD, Daly BD, Putnam JB. Impact of brachytherapy on local recurrence rates after sublobar resection: results from ACOSOG Z4032 (Alliance), a phase III randomized trial for high-risk operable non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 2456-62. PMID 24982457 DOI: 10.1200/Jco.2013.53.4115 |
0.43 |
|
| 2014 |
An MW, Mandrekar SJ, Edelman MJ, Sargent DJ. Exploring the statistical and clinical impact of two interim analyses on the Phase II design with option for direct assignment. Contemporary Clinical Trials. 38: 157-62. PMID 24768938 DOI: 10.1016/J.Cct.2014.04.007 |
0.384 |
|
| 2014 |
Mandrekar SJ. Dose-finding trial designs for combination therapies in oncology. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 65-7. PMID 24323038 DOI: 10.1200/Jco.2013.52.9198 |
0.36 |
|
| 2014 |
Mandrekar SJ, An M, Han Y, Sargent DJ. Clinical utility of tumor measurement (TM)-based metrics in phase II (P2) to predict phase III (P3) overall survival (OS) outcomes using the RECIST 1.1 database. Journal of Clinical Oncology. 32: 6600-6600. DOI: 10.1200/Jco.2014.32.15_Suppl.6600 |
0.341 |
|
| 2014 |
Wigle DA, Mandrekar SJ, Allen-Ziegler K, Gesthalter Y, Holland P, Aubry M, Limburg PJ, Avi S, Szabo E. Pioglitazone as a candidate chemoprevention agent for lung cancer: A pilot window trial in early stage NSCLC. Journal of Clinical Oncology. 32: 1581-1581. DOI: 10.1200/Jco.2014.32.15_Suppl.1581 |
0.432 |
|
| 2014 |
Mandrekar S. How to Design the Trials to Meet the Perspectives of Personalised Cancer Medicine Annals of Oncology. 25: iv9. DOI: 10.1093/Annonc/Mdu294.1 |
0.478 |
|
| 2014 |
Buttar N, Falk GW, Sharma AN, Foster NR, Chowdhury S, Baruah A, Kossak S, Chandra R, Singh I, Iyer PG, Ziegler KA, Romero Y, Marcon NE, Schnell TG, Corley DA, ... ... Mandrekar S, et al. Sa1864 Aspirin Downregulates Cell Survival and mTOR Effector pS6K in Barrett's Esophagus Patients: Data From a Randomized, Double-Blind, Phase II Chemoprevention Trial Gastroenterology. 146: S-315. DOI: 10.1016/S0016-5085(14)61133-1 |
0.43 |
|
| 2014 |
Chak A, Buttar N, Foster NR, Seisler DK, Marcon NE, Schoen RE, Cruz-Correa MR, Falk GW, Sharma P, Hur C, Sharma AN, Baruah A, Chowdhury S, Kossak S, Rodriguez L, ... ... Mandrekar S, et al. Sa1859 Randomized Double Blind Placebo Controlled Phase II Trial of Barrett's Esophagus Chemoprevention With Metformin Gastroenterology. 146: S-314. DOI: 10.1016/S0016-5085(14)61128-8 |
0.368 |
|
| 2013 |
An MW, Mandrekar SJ, Sargent DJ. Application of tumor measurement-based metrics in the real world. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 31: 4374. PMID 24166528 DOI: 10.1200/Jco.2013.52.3662 |
0.398 |
|
| 2013 |
Goetz MP, McKean HA, Reid JM, Mandrekar SJ, Tan AD, Kuffel MA, Safgren SL, McGovern RM, Goldberg RM, Grothey AA, McWilliams R, Erlichman C, Ames MM. UGT1A1 genotype-guided phase i study of irinotecan, oxaliplatin, and capecitabine Investigational New Drugs. 31: 1559-1567. PMID 24114122 DOI: 10.1007/S10637-013-0034-9 |
0.317 |
|
| 2013 |
Kent M, Landreneau R, Mandrekar S, Hillman S, Nichols F, Jones D, Starnes S, Tan A, Putnam J, Meyers B, Daly B, Fernando HC. Segmentectomy versus wedge resection for non-small cell lung cancer in high-risk operable patients. The Annals of Thoracic Surgery. 96: 1747-54; discussion . PMID 23998400 DOI: 10.1016/J.Athoracsur.2013.05.104 |
0.372 |
|
| 2013 |
Sargent DJ, Mandrekar SJ. Statistical issues in the validation of prognostic, predictive, and surrogate biomarkers. Clinical Trials (London, England). 10: 647-52. PMID 23983158 DOI: 10.1177/1740774513497125 |
0.317 |
|
| 2013 |
Mauguen A, Pignon JP, Burdett S, Domerg C, Fisher D, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Sause WT, Dahlberg SE, Crawford J, et al. Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. The Lancet. Oncology. 14: 619-26. PMID 23680111 DOI: 10.1016/S1470-2045(13)70158-X |
0.379 |
|
| 2013 |
Sridhara R, Mandrekar SJ, Dodd LE. Missing data and measurement variability in assessing progression-free survival endpoint in randomized clinical trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2613-20. PMID 23669421 DOI: 10.1158/1078-0432.Ccr-12-2938 |
0.434 |
|
| 2013 |
Mandrekar SJ, An MW, Sargent DJ. A review of phase II trial designs for initial marker validation. Contemporary Clinical Trials. 36: 597-604. PMID 23665336 DOI: 10.1016/J.Cct.2013.05.001 |
0.409 |
|
| 2013 |
Berg AK, Mandrekar SJ, Ziegler KL, Carlson EC, Szabo E, Ames MM, Boring D, Limburg PJ, Reid JM. Population pharmacokinetic model for cancer chemoprevention with sulindac in healthy subjects. Journal of Clinical Pharmacology. 53: 403-12. PMID 23436338 DOI: 10.1002/Jcph.26 |
0.305 |
|
| 2013 |
Ezzalfani M, Zohar S, Qin R, Mandrekar SJ, Deley MC. Dose-finding designs using a novel quasi-continuous endpoint for multiple toxicities. Statistics in Medicine. 32: 2728-46. PMID 23335156 DOI: 10.1002/Sim.5737 |
0.35 |
|
| 2013 |
Limburg PJ, Mandrekar SJ, Aubry MC, Ziegler KL, Zhang J, Yi JE, Henry M, Tazelaar HD, Lam S, McWilliams A, Midthun DE, Edell ES, Rickman OB, Mazzone P, Tockman M, et al. Randomized phase II trial of sulindac for lung cancer chemoprevention. Lung Cancer (Amsterdam, Netherlands). 79: 254-61. PMID 23261228 DOI: 10.1016/J.Lungcan.2012.11.011 |
0.453 |
|
| 2013 |
Dy GK, Mandrekar SJ, Nelson GD, Meyers JP, Adjei AA, Ross HJ, Ansari RH, Lyss AP, Stella PJ, Schild SE, Molina JR, Adjei AA. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small-cell lung cancer: North Central Cancer Treatment Group Study N0528. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 8: 79-88. PMID 23232491 DOI: 10.1097/Jto.0B013E318274A85D |
0.423 |
|
| 2013 |
Witzig TE, Laumann KM, Lacy MQ, Hayman SR, Dispenzieri A, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Hassoun H, Mandrekar SJ, Rajkumar SV. A phase III randomized trial of thalidomide plus zoledronic acid versus zoledronic acid alone in patients with asymptomatic multiple myeloma. Leukemia. 27: 220-5. PMID 22902362 DOI: 10.1038/Leu.2012.236 |
0.376 |
|
| 2013 |
Mandrekar SJ. End points in lung cancer clinical trials: are we ready to step away from overall survival? Lung Cancer Management. 2: 467-470. DOI: 10.2217/Lmt.13.54 |
0.435 |
|
| 2013 |
Kent MS, Landreneau RJ, Mandrekar SJ, Nichols FC, DiPetrillo TA, Meyers BF, Heron DE, Putnam JB, Jones DR, Starnes SL, Daly B, Tan AD, Fernando HC. Factors impacting oncologic outcomes after sublobar pulmonary resection: Results from ACOSOG Z4032 (Alliance), a randomized trial for high-risk operable non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 31: 7524-7524. DOI: 10.1200/Jco.2013.31.15_Suppl.7524 |
0.387 |
|
| 2013 |
Foster NR, Renfro LA, Schild SE, Redman MW, Wang XF, Dahlberg SE, Ding K, Bradbury PA, Ramalingam SS, Gandara DR, Vokes EE, Adjei AA, Mandrekar SJ. Multitrial evaluation of progression-free survival (PFS) as a surrogate endpoint for overall survival (OS) in previously untreated extensive-stage small cell lung cancer (ES-SCLC): An Alliance-led analysis. Journal of Clinical Oncology. 31: 7510-7510. DOI: 10.1200/Jco.2013.31.15_Suppl.7510 |
0.483 |
|
| 2013 |
Molina JR, Mandrekar SJ, Dy GK, Aubry M, Allen Ziegler KL, Dakhil SR, Sachs BA, Nieva JJ, Schild SE, Burroughs K, Williams A, Rudin CM, Adjei AA. A randomized double-blind phase II study of the Seneca Valley virus (NTX-010) versus placebo for patients with extensive stage SCLC (ES-SCLC) who were stable or responding after at least four cycles of platinum-based chemotherapy: Alliance (NCCTG) N0923 study. Journal of Clinical Oncology. 31: 7509-7509. DOI: 10.1200/Jco.2013.31.15_Suppl.7509 |
0.408 |
|
| 2013 |
Mandrekar SJ, An M, Dong X, Grothey A, Bogaerts J, Sargent DJ. Multitrial evaluation of longitudinal tumor measurement (TM)-based metrics for predicting overall survival (OS) using the RECIST 1.1 data warehouse. Journal of Clinical Oncology. 31: 6520-6520. DOI: 10.1200/Jco.2013.31.15_Suppl.6520 |
0.338 |
|
| 2013 |
Ezzalfani M, Zohar S, Mandrekar SJ, Vassal G, Deley ML. Novel toxicity endpoint for dose-finding designs evaluating molecularly targeted agents (MTA). Journal of Clinical Oncology. 31: 2577-2577. DOI: 10.1200/Jco.2013.31.15_Suppl.2577 |
0.328 |
|
| 2013 |
Reungwetwattana T, Mandrekar SJ, Kroneman T, Foster NR, Aubry M, Yi ES, Kerr SE, Yang P, Grothey A, Shridhar V, Voss JS, Kipp B, Molina JR. A Ki-67 proliferation index cutoff value of 1% to predict 5-year RFS and OS in patients with pulmonary carcinoid tumors. Journal of Clinical Oncology. 31: 11119-11119. DOI: 10.1200/Jco.2013.31.15_Suppl.11119 |
0.381 |
|
| 2012 |
Falk GW, Buttar NS, Foster NR, Ziegler KL, Demars CJ, Romero Y, Marcon NE, Schnell T, Corley DA, Sharma P, Cruz-Correa MR, Hur C, Fleischer DE, Chak A, Devault KR, ... ... Mandrekar SJ, et al. A combination of esomeprazole and aspirin reduces tissue concentrations of prostaglandin E(2) in patients with Barrett's esophagus. Gastroenterology. 143: 917-26.e1. PMID 22796132 DOI: 10.1053/J.Gastro.2012.06.044 |
0.396 |
|
| 2012 |
Mauguen A, Le Péchoux C, Saunders MI, Schild SE, Turrisi AT, Baumann M, Sause WT, Ball D, Belani CP, Bonner JA, Zajusz A, Dahlberg SE, Nankivell M, Mandrekar SJ, Paulus R, et al. Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 2788-97. PMID 22753901 DOI: 10.1200/Jco.2012.41.6677 |
0.439 |
|
| 2012 |
Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, Reuter NF, Luyun RF, Dy GK, Marks RS, Schild SE, Jett JR, Adjei AA. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 7: 919-22. PMID 22722792 DOI: 10.1097/Jto.0B013E31824De0D6 |
0.432 |
|
| 2012 |
An MW, Mandrekar SJ, Sargent DJ. A 2-stage phase II design with direct assignment option in stage II for initial marker validation. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 4225-33. PMID 22700865 DOI: 10.1158/1078-0432.Ccr-12-0686 |
0.372 |
|
| 2012 |
Qi Y, Allen Ziegler KL, Hillman SL, Redman MW, Schild SE, Gandara DR, Adjei AA, Mandrekar SJ. Impact of disease progression date determination on progression-free survival estimates in advanced lung cancer. Cancer. 118: 5358-65. PMID 22434489 DOI: 10.1002/Cncr.27528 |
0.396 |
|
| 2012 |
Shi Q, Mandrekar SJ, Sargent DJ. Predictive biomarkers in colorectal cancer: usage, validation, and design in clinical trials. Scandinavian Journal of Gastroenterology. 47: 356-62. PMID 22181041 DOI: 10.3109/00365521.2012.640836 |
0.393 |
|
| 2012 |
Mandrekar SJ, Foster NR, Qi Y, Dy GK, Jatoi A, Molina JR, Jett JR, Stella PJ, Schild SE, Adjei AA, Alliance. Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer. Journal of Clinical Oncology. 30: 7605-7605. DOI: 10.1200/Jco.2012.30.15_Suppl.7605 |
0.409 |
|
| 2012 |
Dy GK, Molina JR, Qi Y, Ansari RH, Thomas SP, Ross HJ, Meyers JP, Adjei A, Mandrekar SJ, Adjei AA. N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2). Journal of Clinical Oncology. 30: 7555-7555. DOI: 10.1200/Jco.2012.30.15_Suppl.7555 |
0.37 |
|
| 2012 |
Chauhan C, Atherton PJ, Satele D, Dueck AC, Soori GS, Johnson DB, Mandrekar SJ, Buckner JC, Sloan JA. Patient satisfaction with participation in phase II/III NCCTG clinical trials: Was it worth it? (N0392). Journal of Clinical Oncology. 30: 6133-6133. DOI: 10.1200/Jco.2012.30.15_Suppl.6133 |
0.39 |
|
| 2012 |
Mandrekar SJ, An M, Meyers J, Grothey A, Bogaerts J, Sargent DJ. Evaluation of Alternate Tumor Metrics and Cut-Points for Response Categorization Using the RECIST 1.1 Data Warehouse Annals of Oncology. 23. DOI: 10.1016/S0923-7534(20)34215-0 |
0.333 |
|
| 2011 |
Molina JR, Dy GK, Foster NR, Allen Ziegler KL, Adjei A, Rowland KM, Aubry M, Flynn PJ, Mandrekar SJ, Schild SE, Adjei AA. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7513. PMID 28023279 DOI: 10.1200/Jco.2011.29.15_Suppl.7513 |
0.419 |
|
| 2011 |
Mandrekar SJ, Qi Y, Allen-Ziegler K, Hillman SL, Redman MW, Schild SE, Gandara DR, Adjei AA. Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: A joint North Central Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7005. PMID 28020086 DOI: 10.1200/Jco.2011.29.15_Suppl.7005 |
0.436 |
|
| 2011 |
Michiels S, Mauguen A, Fisher D, Burdett S, Paulus R, Mandrekar SJ, Belani CP, Shepherd FA, Eisen T, Pang H, Collette L, Le Pechoux C, Pignon J. Evaluation of disease-free survival as surrogate endpoint for overall survival using two individual patient data meta-analyses of adjuvant chemotherapy in operable non-small cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 7004. PMID 28020085 DOI: 10.1200/Jco.2011.29.15_Suppl.7004 |
0.461 |
|
| 2011 |
Mandrekar SJ, Sargent DJ. Design of clinical trials for biomarker research in oncology. Clinical Investigation. 1: 1629-1636. PMID 22389760 DOI: 10.4155/Cli.11.152 |
0.409 |
|
| 2011 |
Jatoi A, Qi Y, Wampfler JA, Busta AJ, Yang P, Mandrekar S. The purported effects of alcohol on appetite and weight in lung cancer patients. Nutrition and Cancer. 63: 1251-5. PMID 21999412 DOI: 10.1080/01635581.2011.607543 |
0.336 |
|
| 2011 |
An MW, Mandrekar SJ, Branda ME, Hillman SL, Adjei AA, Pitot HC, Goldberg RM, Sargent DJ. Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6592-9. PMID 21880789 DOI: 10.1158/1078-0432.Ccr-11-0822 |
0.363 |
|
| 2011 |
Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers B, DiPetrillo TA, Heron DE, Jones DR, Daly BD, Starnes SL, Tan A, Putnam JB. Thirty- and ninety-day outcomes after sublobar resection with and without brachytherapy for non-small cell lung cancer: results from a multicenter phase III study. The Journal of Thoracic and Cardiovascular Surgery. 142: 1143-51. PMID 21872277 DOI: 10.1016/J.Jtcvs.2011.07.051 |
0.411 |
|
| 2011 |
Mandrekar JN, Mandrekar SJ. Systematic reviews and meta-analysis of published studies: an overview and best practices. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 1301-3. PMID 21847059 DOI: 10.1097/Jto.0B013E31822461B0 |
0.309 |
|
| 2011 |
Adjei AA, Blumenschein GR, Mandrekar S, Hillman S, Gatzemeier U, Heigener D. Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clinical Lung Cancer. 12: 212-7. PMID 21726819 DOI: 10.1016/J.Cllc.2011.03.021 |
0.422 |
|
| 2011 |
Fernando HC, Landreneau RJ, Mandrekar SJ, Hillman SL, Nichols FC, Meyers B, DiPetrillo TA, Heron D, Jones DR, Daly BD, Starnes SL, Hatter JE, Putnam JB. The impact of adjuvant brachytherapy with sublobar resection on pulmonary function and dyspnea in high-risk patients with operable disease: preliminary results from the American College of Surgeons Oncology Group Z4032 trial. The Journal of Thoracic and Cardiovascular Surgery. 142: 554-62. PMID 21724195 DOI: 10.1016/J.Jtcvs.2010.10.061 |
0.374 |
|
| 2011 |
Lacy MQ, Allred JB, Gertz MA, Hayman SR, Short KD, Buadi F, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, ... ... Mandrekar SJ, et al. Pomalidomide plus low-dose dexamethasone in myeloma refractory to both bortezomib and lenalidomide: comparison of 2 dosing strategies in dual-refractory disease. Blood. 118: 2970-5. PMID 21690557 DOI: 10.1182/Blood-2011-04-348896 |
0.35 |
|
| 2011 |
Mandrekar SJ, Sargent DJ. All-comers versus enrichment design strategy in phase II trials. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 658-60. PMID 21532916 DOI: 10.1097/Jto.0B013E31820E17Cb |
0.391 |
|
| 2011 |
Kapoor P, Kumar S, Mandrekar SJ, Laumann KM, Dispenzieri A, Lacy MQ, Dingli D, Gertz MA, Kyle RA, Greipp PR, Rajkumar SV, Witzig TE. Efficacy of thalidomide- or lenalidomide-based therapy in proliferative multiple myeloma. Leukemia. 25: 1195-7. PMID 21468037 DOI: 10.1038/Leu.2011.54 |
0.311 |
|
| 2011 |
Reid JM, Walden CA, Qin R, Ziegler KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Bauer BA, Mandrekar SJ, et al. Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prevention Research (Philadelphia, Pa.). 4: 347-53. PMID 21372034 DOI: 10.1158/1940-6207.Capr-10-0313 |
0.409 |
|
| 2011 |
Hobbs BP, Carlin BP, Mandrekar SJ, Sargent DJ. Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics. 67: 1047-56. PMID 21361892 DOI: 10.1111/J.1541-0420.2011.01564.X |
0.355 |
|
| 2011 |
Kapoor P, Rajkumar SV, Dispenzieri A, Gertz MA, Lacy MQ, Dingli D, Mikhael JR, Roy V, Kyle RA, Greipp PR, Kumar S, Mandrekar SJ. Melphalan and prednisone versus melphalan, prednisone and thalidomide for elderly and/or transplant ineligible patients with multiple myeloma: a meta-analysis. Leukemia. 25: 689-96. PMID 21233832 DOI: 10.1038/Leu.2010.313 |
0.408 |
|
| 2011 |
Limburg PJ, Mahoney MR, Ziegler KL, Sontag SJ, Schoen RE, Benya R, Lawson MJ, Weinberg DS, Stoffel E, Chiorean M, Heigh R, Levine J, Della'Zanna G, Rodriguez L, Richmond E, ... ... Mandrekar SJ, et al. Randomized phase II trial of sulindac, atorvastatin, and prebiotic dietary fiber for colorectal cancer chemoprevention. Cancer Prevention Research (Philadelphia, Pa.). 4: 259-69. PMID 21209397 DOI: 10.1158/1940-6207.Capr-10-0215 |
0.416 |
|
| 2011 |
Li Y, Krowka MJ, Qi Y, Katzmann JA, Song Y, Li Y, Mandrekar SJ, Yang P. Alpha1-antitrypsin deficiency carriers, serum alpha 1-antitrypsin concentration, and non-small cell lung cancer survival. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 6: 291-5. PMID 21173712 DOI: 10.1097/Jto.0B013E31820213Fb |
0.373 |
|
| 2011 |
Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer. 117: 1262-71. PMID 20960500 DOI: 10.1002/Cncr.25526 |
0.414 |
|
| 2011 |
Lin Y, Gertz MA, Sims RB, Mandrekar S, Laumann K, LaPlant B, Dispenzieri A, Hayman SR, Buadi FK, Dingli D, Padley D, Gastineau DA, Kumar S, Rajkumar V, Lacy MQ. Matched Case Control Analysis Comparing Long Term Survival of Multiple Myeloma Patients Who Received Stem Cell Transplant with and without Idiotype-Pulsed Dendritic Cell Vaccine Blood. 118: 636-636. DOI: 10.1182/Blood.V118.21.636.636 |
0.377 |
|
| 2010 |
Dy GK, Hillman SL, Rowland KM, Molina JR, Steen PD, Wender DB, Nair S, Mandrekar S, Schild SE, Adjei AA. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326. Cancer. 116: 5686-93. PMID 21218460 DOI: 10.1002/Cncr.25448 |
0.431 |
|
| 2010 |
Lacy MQ, Hayman SR, Gertz MA, Short KD, Dispenzieri A, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Zeldenrust S, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, ... ... Mandrekar SJ, et al. Pomalidomide (CC4047) plus low dose dexamethasone (Pom/dex) is active and well tolerated in lenalidomide refractory multiple myeloma (MM). Leukemia. 24: 1934-9. PMID 20827286 DOI: 10.1182/Blood.V114.22.429.429 |
0.366 |
|
| 2010 |
Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Ziegler KL, Endo C, Molina JR, Schild SE, Adjei AA. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 1346-53. PMID 20651609 DOI: 10.1097/Jto.0B013E3181Ec18C4 |
0.39 |
|
| 2010 |
Mandrekar SJ, Sargent DJ. Randomized phase II trials: time for a new era in clinical trial design. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 932-4. PMID 20581575 DOI: 10.1097/Jto.0B013E3181E2Eadf |
0.439 |
|
| 2010 |
Mandrekar SJ, Qin R, Sargent DJ. Model-based phase I designs incorporating toxicity and efficacy for single and dual agent drug combinations: methods and challenges. Statistics in Medicine. 29: 1077-83. PMID 20419760 DOI: 10.1002/Sim.3706 |
0.348 |
|
| 2010 |
Mandrekar SJ, Sargent DJ. Predictive biomarker validation in practice: lessons from real trials. Clinical Trials (London, England). 7: 567-73. PMID 20392785 DOI: 10.1177/1740774510368574 |
0.32 |
|
| 2010 |
Mandrekar SJ, Qi Y, Hillman SL, Allen Ziegler KL, Reuter NF, Rowland KM, Kuross SA, Marks RS, Schild SE, Adjei AA. Endpoints in phase II trials for advanced non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 5: 3-9. PMID 19884856 DOI: 10.1097/Jto.0B013E3181C0A313 |
0.461 |
|
| 2010 |
Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KL, Stella PJ, Rowland KM, Schild SE, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 614-9. PMID 19841321 DOI: 10.1200/Jco.2009.23.6406 |
0.458 |
|
| 2010 |
Qi Y, Dy GK, Nelson GD, Schild SE, Mandrekar SJ, Adjei AA. Incidence of bleeding and thrombosis among elderly patients (pts) undergoing systemic chemotherapy in advanced non-small cell lung cancer (NSCLC): An analysis of North Central Cancer Treatment Group (NCCTG) trials. Journal of Clinical Oncology. 28: e18093-e18093. DOI: 10.1200/Jco.2010.28.15_Suppl.E18093 |
0.412 |
|
| 2010 |
Dilts DM, Adjei AA, Mandrekar SJ, Buckner JC, Minasian LM, Rienzo M, Ledsky R, Massett H. Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial. Journal of Clinical Oncology. 28: e16505-e16505. DOI: 10.1200/Jco.2010.28.15_Suppl.E16505 |
0.45 |
|
| 2010 |
Lacy M, Gertz MA, Hayman SR, Dispenzieri A, Kumar S, Mikhael J, Stewart AK, Allred J, Mandrekar SJ, Rajkumar SV. Activity of pomalidomide plus dexamethasone (Pom/dex) in dual lenalidomide/bortezomib refractory multiple myeloma (MM). Journal of Clinical Oncology. 28: 8002-8002. DOI: 10.1200/Jco.2010.28.15_Suppl.8002 |
0.348 |
|
| 2010 |
Foster NR, Qi Y, Shi Q, Krook JE, Kugler JW, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ. Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. Journal of Clinical Oncology. 28: 7637-7637. DOI: 10.1200/Jco.2010.28.15_Suppl.7637 |
0.438 |
|
| 2010 |
Mandrekar SJ, Hillman SL, Allen-Ziegler K, Jatoi A, Jett JR, Schild SE, Adjei AA. Impact of the algorithm for declaring exact progression date on progression-free survival (PFS) estimates in advanced lung cancer clinical trials. Journal of Clinical Oncology. 28: 7629-7629. DOI: 10.1200/Jco.2010.28.15_Suppl.7629 |
0.429 |
|
| 2010 |
Dy GK, Mandrekar SJ, Nelson GD, Ross HJ, Ansari RH, Lyss AP, Stella PJ, Schild SE, Molina JR, Adjei AA. A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 28: 7603-7603. DOI: 10.1200/Jco.2010.28.15_Suppl.7603 |
0.379 |
|
| 2010 |
Witzig TE, Mandrekar S, Detweiler-Short K, Lacy MQ, Laumann K, Dispenzieri A, Hayman SR, Kumar S, Reeder CB, Roy V, Lust JA, Gertz MA, Greipp PR, Rajkumar SV. A Phase III Randomized Trial of Thalidomide (THAL) Plus Zoledronic Acid (ZLD) Versus Zoledronic Acid Alone In Patients with Early Stage Multiple Myeloma (MC0289) Blood. 116: 3053-3053. DOI: 10.1182/Blood.V116.21.3053.3053 |
0.418 |
|
| 2010 |
Lin Y, Gertz M, Mandrekar S, Laumann K, Dispenzieri A, Hayman SR, Buadi F, Dingli D, Padley D, Gastineau D, Kumar S, Rajkumar V, Lacy M. Five-Year Follow-up of Randomized, Phase II Trial of Idiotype-Pulsed Dendritic Cell Vaccine with Adjuvant Cytokines In Plateau Phase and Post-Transplant Multiple Myeloma Blood. 116: 1958-1958. DOI: 10.1182/Blood.V116.21.1958.1958 |
0.404 |
|
| 2010 |
Reid JM, Walden C, Qin R, Allen KL, Haslam JL, Rajewski RA, Warndahl R, Fitting CL, Boring D, Szabo E, Crowell J, Perloff M, Jong L, Mandrekar SJ, Ames MM, et al. Abstract CN02-03: Phase 0 chemoprevention trial of SR13668, a novel AKT inhibitor, in normal volunteers Cancer Prevention Research. 3. DOI: 10.1158/1940-6207.Prev-10-Cn02-03 |
0.364 |
|
| 2009 |
Foster NR, Qi Y, Krook JE, Kugler JW, Kuross SA, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ. Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 8085. PMID 27962660 DOI: 10.1200/Jco.2009.27.15_Suppl.8085 |
0.469 |
|
| 2009 |
Jatoi A, Qi Y, Kendall G, Jiang R, McNallan S, Cunningham J, Mandrekar S, Yang P. The cancer anorexia/weight loss syndrome: exploring associations with single nucleotide polymorphisms (SNPs) of inflammatory cytokines in patients with non-small cell lung cancer. Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer. 18: 1299-304. PMID 20012999 DOI: 10.1007/S00520-009-0748-6 |
0.328 |
|
| 2009 |
Mandrekar JN, Mandrekar SJ. Biostatistics: a toolkit for exploration, validation, and interpretation of clinical data. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 1447-9. PMID 20009908 DOI: 10.1097/Jto.0B013E3181C0A329 |
0.313 |
|
| 2009 |
Lacy MQ, Mandrekar S, Dispenzieri A, Hayman S, Kumar S, Buadi F, Dingli D, Litzow M, Wettstein P, Padley D, Kabat B, Gastineau D, Rajkumar SV, Gertz MA. Idiotype-pulsed antigen-presenting cells following autologous transplantation for multiple myeloma may be associated with prolonged survival. American Journal of Hematology. 84: 799-802. PMID 19899131 DOI: 10.1002/Ajh.21560 |
0.402 |
|
| 2009 |
Lacy MQ, Hayman SR, Gertz MA, Dispenzieri A, Buadi F, Kumar S, Greipp PR, Lust JA, Russell SJ, Dingli D, Kyle RA, Fonseca R, Bergsagel PL, Roy V, Mikhael JR, ... ... Mandrekar SJ, et al. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5008-14. PMID 19720894 DOI: 10.1200/Jco.2009.23.6802 |
0.359 |
|
| 2009 |
Mandrekar SJ, Sargent DJ. Genomic advances and their impact on clinical trial design. Genome Medicine. 1: 69. PMID 19638184 DOI: 10.1186/Gm69 |
0.389 |
|
| 2009 |
Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4027-34. PMID 19597023 DOI: 10.1200/Jco.2009.22.3701 |
0.387 |
|
| 2009 |
Qi Y, Schild SE, Mandrekar SJ, Tan AD, Krook JE, Rowland KM, Garces YI, Soori GS, Adjei AA, Sloan JA. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 1075-82. PMID 19546817 DOI: 10.1097/Jto.0B013E3181Ae27F5 |
0.383 |
|
| 2009 |
Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM, Deming RL, Kozelsky TF, Marks RS, Jett JR, Adjei AA. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer. 115: 2721-31. PMID 19402175 DOI: 10.1002/Cncr.24314 |
0.446 |
|
| 2009 |
Mandrekar SJ, Sargent DJ. Clinical trial designs for predictive biomarker validation: one size does not fit all. Journal of Biopharmaceutical Statistics. 19: 530-42. PMID 19384694 DOI: 10.1080/10543400902802458 |
0.408 |
|
| 2009 |
Yang P, Mandrekar SJ, Hillman SH, Allen Ziegler KL, Sun Z, Wampfler JA, Cunningham JM, Sloan JA, Adjei AA, Perez E, Jett JR. Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 4: 479-85. PMID 19347979 DOI: 10.1097/Jto.0B013E31819C7A2C |
0.453 |
|
| 2009 |
Kapoor P, Rajkumar SV, Dispenzieri A, Lacy MQ, Dingli D, Kyle R, Gertz MA, Greipp P.R, Kumar S, Mandrekar SJ. Melphalan and Prednisone (MP) Versus Melphalan, Prednisone and Thalidomide (MPT) as Initial Therapy for Previously Untreated Elderly and/or Transplant Ineligible Patients with Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials. Blood. 114: 615-615. DOI: 10.1182/Blood.V114.22.615.615 |
0.434 |
|
| 2009 |
Mandrekar SJ, Qin R, Sargent DJ. Abstract C53: Dose‐finding designs for combination therapies involving molecularly targeted agents Molecular Cancer Therapeutics. 8. DOI: 10.1158/1535-7163.Targ-09-C53 |
0.37 |
|
| 2009 |
Tong C, Russell S, Lacy M, Federspiel M, Griesmann G, Gertz M, Lowe V, O'Connor M, Kallmes D, Dingli D, Buadi F, Myers R, Peng K, Mandrekar S, Dispenzieri A. A584 Preliminary Results of a Phase I Trial of Intravenous MV-NIS for Relapsed/Refractory Multiple Myeloma Clinical Lymphoma and Myeloma. 9: S88. DOI: 10.1016/S1557-9190(11)70626-6 |
0.341 |
|
| 2008 |
Schild SE, Qi Y, Tan AD, Mandrekar SJ, Adjei AA, Krook JE, Rowland KM, Garces YI, Soori GS, Sloan JA. Baseline quality of life (QOL) as a prognostic factor for overall survival (OS) in patients (Pts) with advanced stage non-small cell lung cancer (A-NSCLC): An analysis of NCCTG studies. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 8076. PMID 27948976 DOI: 10.1200/Jco.2008.26.15_Suppl.8076 |
0.381 |
|
| 2008 |
Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Rowland KM, Deming RL, Kozelsky TF, Jett JR, Marks RS, Adjei AA. Prognostic importance of performance status (PS) in small cell lung cancer (SCLC): A North Central Cancer Treatment Group (NCCTG) investigation. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 19041. PMID 27947768 DOI: 10.1200/Jco.2008.26.15_Suppl.19041 |
0.432 |
|
| 2008 |
Mandrekar JN, Mandrekar SJ. Case-control study design: what, when, and why? Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 3: 1371-2. PMID 19057257 DOI: 10.1097/Jto.0B013E31818Dd97B |
0.324 |
|
| 2008 |
Molina JR, Kaufmann SH, Reid JM, Rubin SD, Gálvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, Mullin RJ, Jewell RC, Felten SJ, Mandrekar S, Adjei AA, Erlichman C. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 7900-8. PMID 19047120 DOI: 10.1158/1078-0432.Ccr-08-0415 |
0.361 |
|
| 2008 |
Reid JM, Mandrekar SJ, Carlson EC, Harmsen WS, Green EM, McGovern RM, Szabo E, Ames MM, Boring D, Limburg PJ. Comparative bioavailability of sulindac in capsule and tablet formulations. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 17: 674-9. PMID 18349286 DOI: 10.1158/1055-9965.Epi-07-2510 |
0.37 |
|
| 2008 |
Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM, Fitch TR, Soori GS, Jett JR, et al. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung Cancer (Amsterdam, Netherlands). 60: 200-7. PMID 18045731 DOI: 10.1016/J.Lungcan.2007.10.003 |
0.482 |
|
| 2008 |
Adjei AA, Mandrekar SJ, Dy GK, Molina JR, Adjei AA, Gandara DR, Ziegler KLA, Stella PJ, Rowland KM, Schild SR, Zinner RG. A phase II second-line study of pemetrexed (pem) in combination with bevacizumab (bev) in patients with advanced non-small cell lung cancer (NSCLC): An NCCTG and SWOG study Journal of Clinical Oncology. 26: 8080-8080. DOI: 10.1200/Jco.2008.26.15_Suppl.8080 |
0.428 |
|
| 2008 |
Mandrekar SJ, Hillman SL, Ziegler KLA, Reuter NF, Rowland KM, Marks RS, Schild SE, Adjei AA. Comparison of progression-free survival (PFS) with best or confirmed response (BR, CR) as an endpoint for overall survival (OS) in advanced non small cell lung cancer (A-NSCLC): A North Central Cancer Treatment Group (NCCTG) investigation Journal of Clinical Oncology. 26: 8021-8021. DOI: 10.1200/Jco.2008.26.15_Suppl.8021 |
0.41 |
|
| 2008 |
Campbell ME, Mandrekar SJ, Hillman SL, Goldberg RM, Adjei AA, Pitot HC, Rowland KM, Grothey A, Buckner JC, Sargent DJ. What is the added value of actual tumor measurements (TM) in predicting overall survival (OS)? The North Central Cancer Treatment Group (NCCTG) findings Journal of Clinical Oncology. 26: 6520-6520. DOI: 10.1200/Jco.2008.26.15_Suppl.6520 |
0.307 |
|
| 2008 |
Lacy MQ, Hayman SR, Gertz MA, Allred JB, Mandrekar SJ, Dispenzieri A, Zeldenrust SR, Kumar S, Greipp PR, Lust JA, Russell SJ, Buadi F, Kyle RA, Bergsagel PL, Fonseca R, et al. Pomalidomide (CC4047) Plus Low-Dose Dexamethasone (Pom/dex) Is Highly Effective Therapy in Relapsed Multiple Myeloma Blood. 112: 866-866. DOI: 10.1182/Blood.V112.11.866.866 |
0.402 |
|
| 2008 |
Lacy MQ, Mandrekar S, Kabat B, Dispenzieri A, Hayman S, Kumar S, Buadi F, Dingli D, Litzow M, Wettstein P, Rajkumar SV, Gastineau D, Gertz MA. Post Autologous Transplantation Consolidation of Multiple Myeloma with Idiotype-Pulsed Antigen Presenting (Dendritic) Cells (APC8020) Is Associated with Prolonged Survival. Blood. 112: 1739-1739. DOI: 10.1182/Blood.V112.11.1739.1739 |
0.357 |
|
| 2008 |
Kapoor P, Kumar S, Greipp PR, Laumann KM, Mandrekar S, Rajkumar SV, Witzig TE. Prognostic Impact of the Plasma Cell Labeling Index (LI) in Newly Diagnosed Myeloma Patients Treated with Thalidomide-Dexamethasone (Thal/Dex) or Lenalidomide-Dexamethasone (Len/Dex). Blood. 112: 1729-1729. DOI: 10.1182/Blood.V112.11.1729.1729 |
0.373 |
|
| 2007 |
Sarkaria JN, Schwingler P, Schild SE, Grogan PT, Mladek AC, Mandrekar SJ, Tan AD, Kobayashi T, Marks RS, Kita H, Miller RC, Limper AH, Leof EB. Phase I trial of sirolimus combined with radiation and cisplatin in non-small cell lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 2: 751-7. PMID 17762343 DOI: 10.1097/Jto.0B013E3180Cc2587 |
0.397 |
|
| 2007 |
Schild SE, Mandrekar SJ, Jatoi A, McGinnis WL, Stella PJ, Deming RL, Jett JR, Garces YI, Allen KL, Adjei AA. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer. 110: 363-8. PMID 17542000 DOI: 10.1002/Cncr.22780 |
0.431 |
|
| 2007 |
Adjei AA, Molina JR, Mandrekar SJ, Marks R, Reid JR, Croghan G, Hanson LJ, Jett JR, Xia C, Lathia C, Simantov R. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 2684-91. PMID 17473200 DOI: 10.1158/1078-0432.Ccr-06-2889 |
0.451 |
|
| 2007 |
Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Bot BM, Martens JM, Wender DB, Soori GS, Moore DF, Kozelsky TF, Jett JR. Phase I North Central Cancer Treatment Group Trial-N9923 of escalating doses of twice-daily thoracic radiation therapy with amifostine and with alternating chemotherapy in limited stage small-cell lung cancer. International Journal of Radiation Oncology, Biology, Physics. 67: 995-1001. PMID 17336213 DOI: 10.1016/J.Ijrobp.2006.10.034 |
0.436 |
|
| 2007 |
Huschka MM, Mandrekar SJ, Schaefer PL, Jett JR, Sloan JA. A pooled analysis of quality of life measures and adverse events data in north central cancer treatment group lung cancer clinical trials. Cancer. 109: 787-95. PMID 17211864 DOI: 10.1002/Cncr.22444 |
0.369 |
|
| 2007 |
Mandrekar SJ, Cui Y, Sargent DJ. An adaptive phase I design for identifying a biologically optimal dose for dual agent drug combinations. Statistics in Medicine. 26: 2317-30. PMID 17016867 DOI: 10.1002/Sim.2707 |
0.339 |
|
| 2007 |
Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 59: 207-15. PMID 16763792 DOI: 10.1007/S00280-006-0259-9 |
0.387 |
|
| 2007 |
Foster NR, Mandrekar SJ, Schild SE, Nelson GD, Jett JR, Adjei AA. Age, gender, performance status and stage outperformed stage alone in predicting overall survival (OS) in patients with small cell lung cancer: A pooled analysis of 1,623 patients from the North Central Cancer Treatment Group Journal of Clinical Oncology. 25: 7723-7723. DOI: 10.1200/Jco.2007.25.18_Suppl.7723 |
0.41 |
|
| 2007 |
Dy GK, Dy PK, Chua PC, Nelson GD, Foster NR, Mandrekar S, Jett JR, Yang P, Deschamps C. Extent of nodal dissection and patient age impact recurrence-free survival (RFS) after surgery for non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 25: 7613-7613. DOI: 10.1200/Jco.2007.25.18_Suppl.7613 |
0.389 |
|
| 2007 |
Adjei AA, Molina JR, Hillman SL, Luyun RF, Reuter NF, Rowland KM, Jett JR, Mandrekar SJ, Schild SE. A front-line window of opportunity phase II study of sorafenib in patients with advanced non-small cell lung cancer: A North Central Cancer Treatment Group study Journal of Clinical Oncology. 25: 7547-7547. DOI: 10.1200/Jco.2007.25.18_Suppl.7547 |
0.451 |
|
| 2007 |
Hillman SL, Sargent DJ, Bot BM, DeMatteo RP, Perez EA, Ballman KV, Mandrekar SJ. Questionable value of attribution when interpreting adverse event data: A joint evaluation by North Central Cancer Treatment Group (NCCTG) and American College of Surgeons Oncology Group (ACOSOG) Journal of Clinical Oncology. 25: 6511-6511. DOI: 10.1200/Jco.2007.25.18_Suppl.6511 |
0.405 |
|
| 2007 |
Schild SE, Mandrekar SJ, Jatoi A, McGinnis WL, Stella PJ, Deming RL, Jett JR, Garces YI, Allen KL, Adjei AA. The value of combined modality therapy in elderly patients with stage III non-small cell lung cancer (NSCLC) Journal of Clinical Oncology. 25: 19503-19503. DOI: 10.1200/Jco.2007.25.18_Suppl.19503 |
0.4 |
|
| 2007 |
Yang P, Mandrekar S, Hillman S, Allen K, Jett J, Perez E, Adjei A. Glutathione pathway genes predict quality of life (QOL) in lung cancer patients: A NCCTG-97–24–51 based study Journal of Clinical Oncology. 25: 18037-18037. DOI: 10.1200/Jco.2007.25.18_Suppl.18037 |
0.365 |
|
| 2007 |
Adjei AA, Dy GK, Mandrekar SJ, Endo C, Salavaggione OE, Molina JR, Schild SE, Adjei AA. PD2-3-5: Pemetrexed pharmacogenomics: haplotype analyses of transport and activation/inactivation gene polymorphisms and the therapeutic outcome in non-small cell lung cancer, an NCCTG N0026 based study Journal of Thoracic Oncology. 2: S445. DOI: 10.1097/01.Jto.0000283367.31058.Ad |
0.31 |
|
| 2007 |
Molina JR, Mandrekar SJ, Rowland K, Reuter NF, Jett JR, Marks R, Schild SE, Adjei AA. D7-07: A phase II NCCTG “Window of Opportunity Front-line” study of the mTOR Inhibitor, CCI-779 (Temsirolimus) given as a single agent in patients with advanced NSCLC Journal of Thoracic Oncology. 2: S413. DOI: 10.1097/01.Jto.0000283298.56701.A0 |
0.468 |
|
| 2006 |
Yang P, Mandrekar SJ, Hillman SL, Allen KL, Sun Z, Wampfler J, Cunningham JM, Jett JR, Adjei AA, Perez EA. Evaluation of platinum-based chemotherapy, glutathione metabolic genes, and survival in advanced non small cell lung cancer: A NCCTG 97-24-51 based study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 24: 13013. PMID 27955426 DOI: 10.1200/Jco.2006.24.18_Suppl.13013 |
0.425 |
|
| 2006 |
Mandrekar SJ, Northfelt DW, Schild SE, Foster NR, Bot B, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Adjei AA, Jett JR. Impact of pretreatment factors on adverse events: a pooled analysis of North Central Cancer Treatment Group advanced stage non-small cell lung cancer trials. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: 556-63. PMID 17409917 DOI: 10.1016/S1556-0864(15)30359-2 |
0.428 |
|
| 2006 |
Mandrekar SJ, Sargent DJ. Pick the winner designs in phase II cancer clinical trials. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: 5-6. PMID 17409819 DOI: 10.1016/S1556-0864(15)31505-7 |
0.456 |
|
| 2006 |
Nowakowski GS, McCollum AK, Ames MM, Mandrekar SJ, Reid JM, Adjei AA, Toft DO, Safgren SL, Erlichman C. A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 12: 6087-93. PMID 17062684 DOI: 10.1158/1078-0432.Ccr-06-1015 |
0.377 |
|
| 2006 |
Mandrekar SJ, Schild SE, Hillman SL, Allen KL, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Chansky K, Kelly K, Adjei AA, Jett JR. A prognostic model for advanced stage nonsmall cell lung cancer. Pooled analysis of North Central Cancer Treatment Group trials. Cancer. 107: 781-92. PMID 16847887 DOI: 10.1002/Cncr.22049 |
0.435 |
|
| 2006 |
Zhang W, Sargent DJ, Mandrekar S. An adaptive dose-finding design incorporating both toxicity and efficacy. Statistics in Medicine. 25: 2365-83. PMID 16220478 DOI: 10.1002/Sim.2325 |
0.352 |
|
| 2006 |
Mandrekar SJ, Huschka MM, Schaefer PL, Jett JR, Adjei AA, Sloan JA. What is the value added of patient reported outcomes relative to physician rated symptom assessments? Journal of Clinical Oncology. 24: 8580-8580. DOI: 10.1200/Jco.2006.24.18_Suppl.8580 |
0.37 |
|
| 2006 |
Hillman SL, Mandrekar SJ, Bot BM, Perez EA, Kugler JW, Adjei AA, Buckner JC, Sargent DJ. Should attribution be considered when interpreting adverse event data: A North Central Cancer Treatment Group (NCCTG) evaluation of a phase III placebo controlled trial Journal of Clinical Oncology. 24: 6006-6006. DOI: 10.1200/Jco.2006.24.18_Suppl.6006 |
0.403 |
|
| 2005 |
Ma CX, Croghan G, Reid J, Hanson L, Mandrekar S, Marks R, Adjei A, Furth A. A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3000. PMID 27945734 DOI: 10.1200/Jco.2005.23.16_Suppl.3000 |
0.363 |
|
| 2005 |
Adjei AA, Mandrekar S, Marks RS, Hanson LJ, Aranguren D, Jett JR, Simantov R, Schwartz B, Croghan GA. A phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3067. PMID 27945592 DOI: 10.1200/Jco.2005.23.16_Suppl.3067 |
0.419 |
|
| 2005 |
Johnson EA, Marks RS, Mandrekar S, Hillman S, Mailliard J, Dentchev T, Reuter N, Jett J, Perez EA. A phase III randomized placebo controlled NCCTG trial of carboxyaminoimidazole (CAI) in patients with advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 7054. PMID 27944503 DOI: 10.1200/Jco.2005.23.16_Suppl.7054 |
0.467 |
|
| 2005 |
Mandrekar SJ, Grothey A, Goetz MP, Sargent DJ. Clinical trial designs for prospective validation of biomarkers. American Journal of Pharmacogenomics : Genomics-Related Research in Drug Development and Clinical Practice. 5: 317-25. PMID 16196501 DOI: 10.2165/00129785-200505050-00004 |
0.427 |
|
| 2005 |
Ma CX, Nair S, Thomas S, Mandrekar SJ, Nikcevich DA, Rowland KM, Fitch TR, Windschitl HE, Hillman SL, Schild SE, Jett JR, Obasaju C, Adjei AA, et al. Randomized phase II trial of three schedules of pemetrexed and gemcitabine as front-line therapy for advanced non-small-cell lung cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 5929-37. PMID 16135464 DOI: 10.1200/Jco.2005.13.953 |
0.465 |
|
| 2005 |
Dy GK, Miller AA, Mandrekar SJ, Aubry MC, Langdon RM, Morton RF, Schild SE, Jett JR, Adjei AA. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. Annals of Oncology : Official Journal of the European Society For Medical Oncology / Esmo. 16: 1811-6. PMID 16087693 DOI: 10.1093/Annonc/Mdi365 |
0.437 |
|
| 2005 |
Dy GK, Mandrekar S, Peethambaram PP, Okuno SH, Croghan GC, Hanson LJ, Furth A, Adjei AA. A phase I trial of celecoxib in combination with docetaxel and irinotecan in patients with advanced cancer. Cancer Chemotherapy and Pharmacology. 56: 623-8. PMID 15999272 DOI: 10.1007/S00280-004-0996-6 |
0.443 |
|
| 2005 |
Dy GK, Thomas JP, Wilding G, Bruzek L, Mandrekar S, Erlichman C, Alberti D, Binger K, Pitot HC, Alberts SR, Hanson LJ, Marnocha R, Tutsch K, Kaufmann SH, Adjei AA. A phase I and pharmacologic trial of two schedules of the proteasome inhibitor, PS-341 (bortezomib, velcade), in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 3410-6. PMID 15867242 DOI: 10.1158/1078-0432.Ccr-04-2068 |
0.445 |
|
| 2005 |
Schild SE, Stella PJ, Brooks BJ, Mandrekar S, Bonner JA, McGinnis WL, Mailliard JA, Krook JE, Deming RL, Adjei AA, Jatoi A, Jett JR. Results of combined-modality therapy for limited-stage small cell lung carcinoma in the elderly. Cancer. 103: 2349-54. PMID 15852407 DOI: 10.1002/Cncr.21034 |
0.467 |
|
| 2005 |
Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Erlichman C, Peethambaram P, Pitot HC, Hanson LJ, Reid JM, Furth A, Cheng S, Martell RE, Kaufmann SH, Adjei AA. A phase I trial of the novel farnesyl protein transferase inhibitor, BMS-214662, in combination with paclitaxel and carboplatin in patients with advanced cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 11: 1877-83. PMID 15756013 DOI: 10.1158/1078-0432.Ccr-04-1769 |
0.439 |
|
| 2005 |
Swensen SJ, Jett JR, Hartman TE, Midthun DE, Mandrekar SJ, Hillman SL, Sykes AM, Aughenbaugh GL, Bungum AO, Allen KL. CT screening for lung cancer: five-year prospective experience. Radiology. 235: 259-65. PMID 15695622 DOI: 10.1148/Radiol.2351041662 |
0.324 |
|
| 2005 |
Dy GK, Bekele L, Hanson LJ, Furth A, Mandrekar S, Sloan JA, Adjei AA. Complementary and alternative medicine use by patients enrolled onto phase I clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4810-5. PMID 15570083 DOI: 10.1200/Jco.2004.03.121 |
0.4 |
|
| 2005 |
Mandrekar SJ, Nagaraja HN, Berntson GG. Statistical modelling of the differences between successive R-R intervals. Statistics in Medicine. 24: 437-51. PMID 15532101 DOI: 10.1002/Sim.1948 |
0.478 |
|
| 2005 |
Garces YI, Okuno SH, Schild SE, Mandrekar SJ, Mailliard JA, Kahanic SP, Rao RM, Moore DF, Kozelsky TF, Jett JR. A phase I/II NCCTG trial of escalating doses of twice daily thoracic radiation therapy (TRT) in limited-stage small cell lung cancer (LSCLC) Journal of Clinical Oncology. 23: 7163-7163. DOI: 10.1200/Jco.2005.23.16_Suppl.7163 |
0.379 |
|
| 2005 |
Dy GK, Miller AA, Mandrekar S, Aubry M-, Langdon RM, Schild SE, Jett JR, Adjei AA, Calgb N. A phase II NCCTG/CALGB trial of imatinib (STI571) in patients (pts) with c-kit-expressing relapsed small cell lung cancer (SCLC) Journal of Clinical Oncology. 23: 7048-7048. DOI: 10.1200/Jco.2005.23.16_Suppl.7048 |
0.39 |
|
| 2005 |
Goetz MP, Safgren S, Goldberg RM, Grothey AF, Mandrekar SJ, Reid JM, Erlichman C, Adjei AA, Rubin J, Ames MM. A phase I dose escalation study of irinotecan (CPT-11), oxaliplatin (Oxal), and capecitabine (Cap) within three UGT1A1 TA promoter cohorts (6/6, 6/7, and 7/7) Journal of Clinical Oncology. 23: 2014-2014. DOI: 10.1200/Jco.2005.23.16_Suppl.2014 |
0.336 |
|
| 2005 |
Mandrekar SJ, Schild SE, Hillman SL, Foster NR, Adjei AA, Marks RS, Mailliard JA, Krook JE, Maksymiuk AW, Jett JR. A pooled analysis of 11 NCCTG advanced stage non-small cell lung cancer (NSCLC) trials reveals the importance of baseline blood counts on clinical outcomes Journal of Clinical Oncology. 23: 7193-7193. DOI: 10.1016/S0169-5002(05)80413-1 |
0.429 |
|
| 2005 |
Midthun D, Jett J, Swensen S, Hartman T, Aughenbaugh G, Mandrekar S, Sykes A, Bungum A. PD-058 Screening for lung cancer with low-dose spiral computed tomography (SCT): 5-year results of the mayo clinic trial Lung Cancer. 49: S83. DOI: 10.1016/S0169-5002(05)80391-5 |
0.364 |
|
| 2004 |
Adjei AA, Nair S, Reuter N, Mandrekar S, Kuross S, Rowland KM, Steen P, Hillman S, Schild S, Jett J. Pemetrexed (Pem)/gemcitabine (Gem) as front-line therapy for advanced NSCLC: A randomized, phase II trial of three schedules. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7070. PMID 28016145 DOI: 10.1200/Jco.2004.22.14_Suppl.7070 |
0.424 |
|
| 2004 |
Schild SE, Stella PJ, Brooks BJ, Mandrekar S, Bonner JA, McGinnis WL, Nikcevich DA, Adjei AA, Jatoi A, Jett JR. The Results of combined modality therapy for limited stage small cell lung cancer (LD-SCLC) in the elderly. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 7043. PMID 28016065 DOI: 10.1200/Jco.2004.22.90140.7043 |
0.483 |
|
| 2004 |
Mandrekar S, Dy GK, Furth A, Bekele L, Hanson L, Sloan J, Adjei AA. Complementary and alternative medicine (CAM) use by patients enrolled in phase I clinical trials. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 8053. PMID 28015843 DOI: 10.1200/Jco.2004.22.90140.8053 |
0.456 |
|
| 2004 |
Haluska P, Toft DO, Steinmetz SM, Furth A, Mandrekar S, Stensgard BA, McCollum AK, Hanson LJ, Adjei AA, Erlichman C. A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamycin (17-AAG) and cisplatin (CDDP) in solid tumor patients. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3058. PMID 28015211 DOI: 10.1200/Jco.2004.22.14_Suppl.3058 |
0.396 |
|
| 2004 |
Rao RD, Reid JM, Goetz MP, Furth AF, Mandrekar SJ, Adjei AA, Ames MM, Safgren SL, Erlichman C, Pitot HC. Phase I trial of OSI-774 and CPT-11 in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3053. PMID 28015206 DOI: 10.1200/Jco.2004.22.14_Suppl.3053 |
0.392 |
|
| 2004 |
Dy GK, Bruzek LM, Croghan GA, Mandrekar S, Peethambaram P, Hanson LJ, Erlichman C, Cheng S. A phase I trial of the farnesyltransferase (FT) inhibitor, BMS-214662 (B) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 3066. PMID 28014773 DOI: 10.1200/Jco.2004.22.14_Suppl.3066 |
0.381 |
|
| 2004 |
Atherton PJ, Jasperson BJ, Sloan JA, Mandrekar S, Smith DJ, Erlichman C, Adjei AA. A pooled analysis of demographic characteristics and clinical outcomes of phase I oncology clinical trials, the Mayo Clinic experience. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 9724. PMID 28014387 DOI: 10.1200/Jco.2004.22.90140.9724 |
0.401 |
|
| 2004 |
Erlichman C, Toft D, Reid J, Goetz M, Ames M, Mandrekar S, Ajei A, McCollum A, Ivy P. A phase I trial of 17-allylamino-geldanamycin (17AAG) in patients with advanced cancer Journal of Clinical Oncology. 22: 3030-3030. DOI: 10.1200/Jco.2004.22.90140.3030 |
0.434 |
|
| Show low-probability matches. |